Rivercell announced USD 25 million in seed funding on 7 October 2026, led by HV Capital. Yann Fleureau and Eric Durand founded the Paris company to combine experimental cell data with AI models that predict how human cells respond to treatment. The team is developing infrastructure for drug discovery, bringing laboratory information into computational models. Its work aims to help researchers study potential responses before committing to later development stages. The funding connects a research-focused technology approach with institutional capital. Rivercell's story sits within life sciences, where the purpose of the AI system is to support the development of medicines.
Rivercell launches with USD 25m seed funding
HV Capital leads investment in AI models of human cell responses

Keep reading
More Funding

BrightAI secures USD 97 million to scale physical AI infrastructure
Smith Point Capital led the investment in sensor based monitoring for essential services.

Dcubed raises EUR 27.2 million to expand space hardware production
Warsaw Equity Group led the oversubscribed Series A plus round for the German manufacturer.

Linq raises USD 90 million to expand AI powered mobile infrastructure
Andreessen Horowitz led the Series B and partner Ben Horowitz joined the board.


